We are not formally constituted as a company yet. We are waiting on a seed grant resolution to create the startup. The idea of creating this company comes from a project of our research group, the Group of Materials Engineering (GEMAT) of Institut Químic de Sarrià (IQS).
We have developed a surface engineering technology that allows the immobilization of collagen-based hydrogels onto the surface of any substrate. As the methodology can be used to treat any substrate, it has a high versatility and can be used for a wide range of applications. Using this proprietary technology, we have built a heterogeneous osteochondral scaffold with a great potential to be used as a regenerative therapy for osteoarthritis.
Osteoarthritis (OA), is the most common form of arthritis and it is considered one of the most disabling diseases in developed countries. It affects 240 million people globally and its prevalence is increasing. The increase of its risk factors suggest that the increasing prevalen...
We are not formally constituted as a company yet. We are waiting on a seed grant resolution to create the startup. The idea of creating this company comes from a project of our research group, the Group of Materials Engineering (GEMAT) of Institut Químic de Sarrià (IQS).
We have developed a surface engineering technology that allows the immobilization of collagen-based hydrogels onto the surface of any substrate. As the methodology can be used to treat any substrate, it has a high versatility and can be used for a wide range of applications. Using this proprietary technology, we have built a heterogeneous osteochondral scaffold with a great potential to be used as a regenerative therapy for osteoarthritis.
Osteoarthritis (OA), is the most common form of arthritis and it is considered one of the most disabling diseases in developed countries. It affects 240 million people globally and its prevalence is increasing. The increase of its risk factors suggest that the increasing prevalence will continue, together with both personal and societal economic costs due to healthcare use. Its symptoms cause a significant impact in day-to-day function, loss of independence and reduced quality of life. There are no drugs approved which prevent, treat or restrain OA. The available treatments focus on reducing pain and the symptoms without providing a cure for OA. Thus, there is an imperative need for treatments that instead of focusing on symptoms reduction target the illness itself, providing means for tissue repair and avoid the need for invasive surgical procedures.

We present a biomaterial construct with a great potential to be used as scaffold that provides a suitable environment for tissue repair. It would be indicated for early stage OA and has a great potential for preventing the need for invasive surgical procedures such as total knee replacement. With the creation of the startup, we aim to bring our product closer to the market by the prototype development, preclinical and clinical testing.

Moreover, our hydrogel-immobilizing technology has attracted interest in other fields, such as dentistry. Thus, we plan on licensing this technology and expand its field of application.
More information

Employees

Anna Mas
Admin
Anna Mas CEO Young scientist with a great motivation to bring the research from the academy to the market. Motivated and persistent.